Image

Sustainable Diets and Cardiometabolic Health

Sustainable Diets and Cardiometabolic Health

Recruiting
45-70 years
All
Phase N/A

Powered by AI

Overview

This study aims to investigate the effects of sustainable diets on traditional and novel cardiometabolic risk factors.

The primary objective is:

• To test the effects of a sustainable diet on traditional cardiometabolic risk factors, specifically, a metabolic health score.

The secondary objectives are:

  • To test the effects of sustainable diets on blood lipids, inflammatory markers, glucose markers, and anthropometric and body composition markers.
  • To test the effect of sustainable diets on circulating metabolomic profiles.
  • To test the effects of sustainable diets on circulating proteomic profiles.

Participants will receive dietary interventions of a sustainable health diet, namely the PHD diet (Planetary Health Diet), an ovo-lacto-vegetarian diet, or a habitual diet following general recommendations for a healthy diet without advice on consumption of animal products. The three-arm parallel RCT will involve adults (45-70 years old) at cardiovascular risk.

The primary hypothesis is that targeted interventions to adopt sustainable diets will have beneficial effects on cardiometabolic biomarkers, metabolomic, and proteomic profiles, compared to the habitual diet in individuals at cardiovascular risk.

Description

Background: To promote sustainable diets for planetary and human health, the EAT-Lancet Commission called for a global dietary transformation by 2050, advocating a dietary pattern shift to align food systems with environmental sustainability and human health. The Planetary Health Diet (PHD) promotes a plant-based approach, emphasizing the consumption of whole grains, fruits, vegetables, nuts, and legumes, and limited amounts of seafood and poultry, while discouraging excessive intake of red and processed meat, added sugar, refined grains, and starchy vegetables. Despite the promotion of the popular EAT-Lancet diet, there is no Randomized Controlled Trial (RCT) evaluating the impact of this pattern on established and novel cardiometabolic biomarkers. The trial design addresses the recognized lack of RCTs evaluating changes in multi-omic profiles by adhering to different dietary interventions; the lack of RCTs on sustainable diets that consider environmental aspects; and overcome limitations of potential reverse causation and other biases from observational studies.

Investigation plan: Participants will be randomized to receive advice on changes in the overall dietary pattern from specialized dietitians. Participants in the PHD diet group will be guided to follow the EAT-Lancet recommendations adapted to be nutritionally adequate and culturally acceptable in Denmark (a high-quality plant-based diet with a low allowance of intake of eggs, dairy, chicken, and fish, but strictly avoiding red and processed meat). Participants in the vegetarian diet group will be advised to adhere to a stricter plant-based diet with an intake of eggs and dairy but avoiding chicken, fish, and red and processed meat, and no recommendations on food quantity or the environment. The two interventions will be compared with the control group, where participants will follow their habitual diet without specific advice on the consumption of animal products. The present RCT is not a weight loss trial, thus no total calorie restriction will be advised, and physical activity will not be promoted. A maximum alcohol consumption limited to 100 grams/week for men and women drinkers will be allowed.

Dietary considerations: The comparisons will allow us to address the unanswered question of whether the inclusion of moderate amounts of animal-based products in the context of a climate-friendly diet is superior to a stricter vegetarian diet. Vegan diets were not considered because of the difficulty in adherence in European settings and the potential for micronutrient deficiencies. The higher between-group contrast, considering both health and environmental impact is expected to be found for PHD vs control group.

The study will include an information meeting, screening visit, baseline visit, two visits during the intervention (1 month and 3 months), and a final visit at 6 months. Additionally, two group visits (at 2 and 4 months) will be conducted. Outcome parameters (a metabolic health score and its components) will be measured using blood samples obtained at baseline, 3 months, and final visit. Urine samples will be collected for the research biobank at the baseline, 1 month, 3 months, and final visit. Fecal samples will be collected at baseline and the final visit. Participants will wear continuous glucose monitors (CGM) for 10 days at baseline and at the end of follow-up.

Participants will have access to a study app that will include a timeline of the study, study materials including dietary recommendations, meal planners and recipes according to the intervention group, and instructions for collecting biosamples. Participants will also use the app to respond to self-reported questionnaires. Food boxes containing targeted products for each intervention will be distributed to participants at baseline, 1 month, and 3 months.

Participants will attend two group visits (5-15 participants), where they will receive educational material, information about the science behind the trial and have the opportunity to share experiences with their peers.

Eligibility

Inclusion Criteria:

  • Adults (males and females) between 45 and 70 years of age at the time of inclusion.
  • Participants must have at least two metabolic alterations: 1) Waist Circumference (WC) \>102 cm (males) or \>88 cm (females); 2) self-reported medication for blood pressure or blood pressure \>130/85 mmHg; 3) self-reported prediabetes or non-fasting plasma glucose 140-199 mg/dL (prediabetes); 4) self-reported lipid-lowering medication or diagnosis of impaired blood lipids (triglycerides: ≥ 150 mg/dL; and HDL: men: \< 40 mg/dL and women: \< 50 mg/dL).
  • Participants are not institutionalized, able to read and provide consent before participation, and willing to attend in-person visits at the study site.
  • Participants should have access to a smartphone and computer, or tablet and must be internet-literate.
  • Understand Danish both in writing and when spoken.

Exclusion Criteria:

  • Participants with any serious illness or history of cancer within the past 5 years (except adequately treated localized basal cell skin cancer or in situ uterine cervical cancer).
  • Diagnosed with diabetes mellitus, CVD event (myocardial infarction, revascularization procedure, or stroke), or atrial fibrillation.
  • Participants with diagnosed psychiatric conditions or cognitive impairment.
  • Current smokers including all kinds of nicotine-containing products.
  • BMI \>35 kg/m2.
  • Known or suspected abuse of alcohol or recreational drugs. Regular alcohol consumption exceeding the Danish national guidelines (i.e., more than 10 standard drinks per week or more than 4 drinks on any single day) will be excluded.
  • Pregnancy or planning a pregnancy in the next year.
  • Not willing to consume chicken and fish or not willing to make dietary changes related to the intervention.
  • Participants with multiple food allergies that could hinder adherence to the intervention.
  • Any other issue that makes the project responsible (PI or medical responsible) doubt the eligibility of the volunteer.

Study details
    Cardiometabolic Diseases

NCT07189676

University of Copenhagen

1 February 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.